Jump to Navigation

Publicaties 2009

Publicaties 2009:

  • Biemond BJ. Preventie en behandeling van sikkelcelziektegerelateerde complicaties. NED TIJDSCHR HEMATOL 2009;6(2):56-61.   
 
  • Biemond BJ, Kerkhoffs JLH. Indicaties voor bloedtransfusie bij sikkelcelziekte. TIJDSCHR BLOEDTRANSFUSIE 2009;2(4):118-124.  

 

  • Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, de Haas M, de Boer M, Roos D, Kuijpers TW. Copy Number Variation at the FCGR Locus Includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. HUM MUTAT 2009;30(5):E640-E650.     [ PubMed ]

 

  • Cornelissen JJ, van der Holt B, Verhoef GEG, van't Veer MB, van Oers MHJ, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW [Investigators: Cornelissen JJ, van der Holt B, Verhoef GEG, van't Veer MB, van Oers MHJ, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW]. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. BLOOD 2009;113(6):1375-1382.     [ PubMed ]

 

  • Daniels G, Castilho L, Flegel WA, Fletcher A, Garratty G, Levene C, Lomas-Francis C, Moulds JM, Moulds JJ, Olsson ML, Overbeeke M, Poole J, Reid ME, Rouger P, van der Schoot E , Scott M, Sistonen P, Smart E, Storry JR, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T [Investigators: Daniels GL, Castilho L, Flegel WA, Garratty G, Lomas-Francis C, Moulds JJ, Moulds JM, Olsson ML, Overbeeke MAM, Poole J, Reid ME, Rouger P, van der Schoot CE, Scott M, Sistonen P, Smart E, Storry JR, Tani Y, Yu LC, Wendel S, Westhoff CM, Yahalom V, Zelinski T]. International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao report. VOX SANG 2009;96(2):153-156.     [ PubMed ]

 

  • Daniels G, van der Schoot CE, Gassner C, Olsson ML. Report of the third international workshop on molecular blood group genotyping. VOX SANG 2009;96(4):337-343.     [ PubMed ]

 

  • de Haas V , dee R, Cheroutre G, van den Berg H, van der Schoot CE. Gene expression profile of slowly responding subclones might represent different profiles already at diagnosis and might be used for prediction of outcome. LEUKEMIA 2009;23(4):816-819.     [ PubMed ]

 

  • de Heer K, Visser CE, Biemond BJ, Blijlevens NMA. De plaats van primaire antimycotische profylaxe bij intensieve chemotherapie en allogene stamceltransplantatie. NED TIJDSCHR HEMATOL 2009;6(7):268-275.  

 

  • de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, de Boer JP, van Glabbeke M. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. HAEMATOL-HEMATOL J 2009;94(1):70-77.     [ PubMed ]

 

  • de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Hagenbeek A, Horning S, Lister A, Raemaekers J, Salles G, Gascoyne RD, Weller E. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J CLIN PATHOL 2009;62(2):128-138.     [ PubMed ]

 

  • Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J NUCL MED 2009;50(11):1837-1843.     [ PubMed ]

 

  • Enzler T, Kater AP, Zhang W, Widhopf GF II, Chuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. Chronic lymphocytic leukemia of E mu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. BLOOD 2009;114(20):4469-4476.  

 

  • Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A. Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma. J CLIN ONCOL 2009;27(36):6094-6100.     [ PubMed ]

 

  • Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, Mellink CHM, van Oers MHJ, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. LEUKEMIA RES 2009;33(9):1276-1281.     [ PubMed ]

 

  • Hagenbeek A. Maintenance or Eradication of Residual Disease in Indolent Lymphoma: Where Do We Stand?. J CLIN ONCOL 2009;27(10):1540-1542.     [ PubMed ]

 

  • Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G. Biomarkers and Prognosis in Malignant Lymphomas. CLIN LYMPHOMA MYELOM 2009;9(2):160-166.     [ PubMed ]

 

  • Heutte N, Flechtner HH, Mounier N, Mellink WAM, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WGJM, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, van den Neste E, Creemers GJM, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. LANCET ONCOL 2009;10(12):1160-1170.     [ PubMed ]

 

  • Jak M, Mous R, Remmerswaal EBM, Spijker R, Jaspers A, Yagüe A, Eldering E, van Lier RAW, van Oers MHJ. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. LEUKEMIA LYMPHOMA 2009;50(5):788-801.     [ PubMed ]

 

  • Kager LM, Kersten MJ, Kloppenborg RP, van Oers R, van den Born BJ. Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma. BMJ CASE REP 2009;2009 [aheadofprint]     [ PubMed ]

 

  • Kater AP , van Oers MHJ. De tyrosinekinaseremmer dasatinib voor behandeling van chemotherapie-refractaire chronische lymfatische leukemie: de D'ACCORD-studie. NED TIJDSCHR HEMATOL 2009;6(8):317-320.

 

  • Kerkhoffs JLH, Smiers FJ, Biemond BJ. Overwegingen en dilemma's rond allogene stamceltransplantatie voor sikkelcelziekte. NED TIJDSCHR HEMATOL 2009;6(5):173-181.  

 

  • Kim YS, Nur E, van Beers EJ, Truijen J, Davis SCAT, Biemond BJ, van Lieshout JJ. Dynamic Cerebral Autoregulation in Homozygous Sickle Cell Disease. STROKE 2009;40(3):808-814.     [ PubMed ]

 

  • Koelewijn JM. Detection and prevention of pregnancy immunisation. The OPZI study. s.l.: s.n.; 2009. (229pp.) (ISBN 9789036736770) (PhD thesis. Supervisor(s):  van der Schoot CE, Bonsel GJ; co-supervisor(s):  de Haas M, Vrijkotte TGM) [ UvA Dissertations Online ]
 
  • Koelewijn JM, de Haas M, Vrijkotte TGM, van der Schoot CE, Bonsel GJ. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG-INT J OBSTET GY 2009;116(10):1307-1314.     [ PubMed ]

 

  • Koelewijn JM, Vrijkotte TGM, de Haas M, van der Schoot CE, Bonsel GJ. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG-INT J OBSTET GY 2009;116(5):655-664.     [ PubMed ]

 

  • Kroot JJC, Laarakkers CMM, Kenma EHJM, Biemond BJ, Swinkels DW. Regulation of serum hepcidin levels in sickle cell disease. HAEMATOL-HEMATOL J 2009;94(6):885-887.  

 

  • Landburg PP, Nur E, Maria N, Brandjes DPM, Biemond BJ, Schnog JB, Duits AJ. Elevated Circulating Stromal-Derived Factor-1 Levels in Sickle Cell Disease. ACTA HAEMATOL-BASEL 2009;122(1):64-69.  

 

  • Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G. High-dose daunorubicin in older patients with acute myeloid leukemia. NEW ENGL J MED 2009;361(13):1235-1248.  

 

  • Mous R, Jaspers A, Luijks DMP, Mellink CHM, van Oers MHJ, Kater AP , Eldering E. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. LEUKEMIA 2009;23(7):1352-1355.     [ PubMed ]

 

  • Nur E, Kim YS, Truijen J, van Beers EJ, Davis SCAT, Brandjes DP, Biemond BJ, van Lieshout JJ. Cerebrovascular reserve capacity is impaired in patients with sickle cell disease. BLOOD 2009;114(16):3473-3478.     [ PubMed ]

 

  • Olde Nordkamp L, Mellink C, van der Schoot E, van den Berg H. Karyotyping, FISH, and PCR in acute lymphoblastic leukemia: competing or complementary diagnostics?. J PEDIAT HEMATOL ONC 2009;31(12):930-935.     [ PubMed ]

 

  • Osterborg A, Foà R, Bezares RF, Dearden C, Dyer MJS, Geisler C, Lin TS, Montillo M, van Oers MHJ, Wendtner CM, Rai KR. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. LEUKEMIA 2009;23(11):1980-1988.     [ PubMed ]

 

  • Samani NJ, Deloukas P, Erdmann J, Hengstenberg C, Kuulasmaa K, McGinnis R, Schunkert H, Soranzo N, Thompson J, Tiret L, Ziegler A, Trip MD. Large scale association analysis of novel genetic loci for coronary artery disease. ARTERIOSCL THROM VAS 2009;29(5):774-780.     [ PubMed ]

 

  • Schattenberg AVMB, Schouten HC, Verdonck LF, Willemze R, van der Lelie J, Huijgens PC, van Imhoff GW, van Biezen A, Brand R, Hagenbeek A, de Witte T, Cornelissen JJ. Allogene stamceltransplantatie in Nederland. NED TIJDSCHR GENEESKD 2009;153(9):380-385.     [ PubMed ]

 

  • Strijbos MH, Landburg PP, Nur E, Teerlink T, Leebeek FWG, Rijneveld AW, Biemond BJ, Sleijfer S, Gratama JW, Duits AJ, Schnog JJB. Circulating endothelial cells: A potential parameter of organ damage in sickle cell anemia?. BLOOD CELL MOL DIS 2009;43(1):63-67.  

 

  • Stuijver DJF, Sohne M, Hagenbeek A, Soesan M. Een patient met een non-Hodgkin lymfoom van lage maligniteitsgraad. Van kwaad tot erger.. NED TIJDSCHR HEMATOL 2009;6:279-284.  

 

  • Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM. Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers. CLIN CHEM 2009;55(7):1316-1326.     [ PubMed ]

 

  • Takkenberg RB, Zaaijer HL, ten Cate DF, Biemond BJ, Jansen PLM, Reesink HW. Reactivatie van het hepatitis B-virus bij patiënten met een hematologische maligniteit. NED TIJDSCHR GENEESKD 2009;153(19):926-931.     [ PubMed ]

 

  • van Beem RT, Nur E, Zwaginga JJ, Landburg PP, van Beers EJ, Duits AJ, Brandjes DP, Lommerse I, de Boer HC, van der Schoot CE, Schnog JJB, Biemond BJ. Elevated endothelial progenitor cells during painful sickle cell crisis. EXP HEMATOL 2009;37(9):1054-1059.     [ PubMed ]

 

  • van Beem RT, Verloop RE, Kleijer M, Noort WA, Loof N, Koolwijk P, van der Schoot CE, van Hinsbergh VWM, Zwaginga JJ. Blood outgrowth endothelial cells from cord blood and peripheral blood: angiogenesis-related characteristics in vitro. J THROMB HAEMOST 2009;7(1):217-226.     [ PubMed ]

 

  • van Beers EJ, Schaap MCL, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, Meijers JCM, Biemond BJ. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. HAEMATOL-HEMATOL J 2009;94(11):1513-1519.     [ PubMed ]

 

  • van Beers E, Schnog JJ, Biemond B. Lung function tests in patients with sickle cell disease: A reply. AM J HEMATOL 2009;84(5):310-311.     [ PubMed ]

 

  • van der Schoot CE, de Haas M, Engelfriet CP, Reesink HW, Panzer S, Jungbauer C, Schwartz DMW, Mayr WR, Castilho L, St-Louis M, Long A, Denomme G, Semple E, Fernandes B, Flegel WA, Wagner F, Doescher A, Poli F, Villa MA, Paccapelo C, Veldhuisen B, Nogués N, Muñiz-Diaz E, Daniels G, Martin P, Finning K, Reid ME. Genotyping for red blood cell polymorphisms. VOX SANG 2009;96(2):167-179.     [ PubMed ]

 

  • van der Schoot CE, Veldhuisen B, de Haas M. Will Genotyping Replace Serology in Future Routine Blood Grouping? Opinion 5. TRANSFUS MED HEMOTH 2009;36(3):234-235.

 

  • van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. NETH J MED 2009;67(7):251-259.     [ PubMed ]

 

  • van Oers MHJ. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma:moving targets. NETH J MED 2009;67(8):309-310.     [ PubMed ]

 

  • van 't Veer MB, de Jong D, Mackenzie M, Kluin-Nelemans HC, van Oers MHJ, Zijlstra J, Hagenbeek A, van Putten WLJ. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. BRIT J HAEMATOL 2009;144(4):524-530.     [ PubMed ]

 

  • van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MTB, Fliers E, Gerdes VEA, Büller HR, Brandjes DPM. Hypercoagulable State in Cushing's Syndrome: A Systematic Review. J CLIN ENDOCR METAB 2009;94(8):2743-2750.     [ PubMed ]

 

  • Veldhuisen B, van der Schoot CE, de Haas M. Blood group genotyping: from patient to high-throughput donor screening. VOX SANG 2009;97(3):198-206.     [ PubMed ]

 

  • Watkins NA, Gusnanto A, de Bono B, de S, Miranda-Saavedra D, Hardie DL, Angenent WGJ, Attwood AP, Ellis PD, Erber W, Foad NS, Garner SF, Isacke CM, Jolley J, Koch K, Macaulay IC, Morley SL, Rendon A, Rice KM, Taylor N, Thijssen-Timmer DC, Tijssen MR, van der Schoot CE, Wernisch L, Winzer T, Dudbridge F, Buckley CD, Langford CF, Teichmann S, Göttgens B, Ouwehand WH. A HaemAtlas: characterizing gene expression in differentiated human blood cells. BLOOD 2009;113(19):e1-e9.     [ PubMed ]

 

  • Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MHJ, Mertens D, Döhner H, Stilgenbauer S. miR-34a as part of the resistance network in chronic lymphocytic leukemia. BLOOD 2009;113(16):3801-3808.     [ PubMed ]
Auteur: B.M.J.M. Odijk, versie: 1.0, 18-02-2021